These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8827244)

  • 1. Misprint of dosage interval for liposomal doxorubicin hydrochloride.
    Subach RA; Ruble J
    Am J Health Syst Pharm; 1996 Jul; 53(14):1727. PubMed ID: 8827244
    [No Abstract]   [Full Text] [Related]  

  • 2. Liposomal doxorubicin (Doxil).
    Porche DJ
    J Assoc Nurses AIDS Care; 1996; 7(2):55-9. PubMed ID: 8679968
    [No Abstract]   [Full Text] [Related]  

  • 3. DOXIL approved by FDA.
    AIDS Patient Care; 1995 Dec; 9(6):306. PubMed ID: 11361446
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiotoxicity after liposomal anthracyclines.
    Young AM; Dhillon T; Bower M
    Lancet Oncol; 2004 Nov; 5(11):654. PubMed ID: 15522651
    [No Abstract]   [Full Text] [Related]  

  • 5. Liposomal doxorubicin in AIDS-related Kaposi's sarcoma.
    Hengge UR; Brockmeyer NH; Baumann M; Reimann G; Goos M
    Lancet; 1993 Aug; 342(8869):497. PubMed ID: 8102452
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma.
    Bennett CL; Golub RM; Stinson TJ; Aboulafia DM; von Roenn J; Bogner J; Goebel FD; Stewart S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(5):460-5. PubMed ID: 9715842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA approves KS drug. Food and Drug Administration. Florida Department of Health and Rehabilitation Services.
    AIDS Alert; 1996 Jan; 11(1):11-2. PubMed ID: 11363227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal doxorubicin: new preparation. Useful in Kaposi's sarcoma.
    Prescrire Int; 1998 Jun; 7(35):69-70. PubMed ID: 10342919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KS treatment inches forward.
    Vazquez E
    Posit Aware; 1996; 7(5):9. PubMed ID: 11363790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin liposome formulation gains marketing approval.
    Am J Health Syst Pharm; 1996 Jan; 53(2):116, 119. PubMed ID: 8653476
    [No Abstract]   [Full Text] [Related]  

  • 11. Liposomal doxorubicin.
    Linsky KF; Ignoffo RJ
    Cancer Pract; 1996; 4(5):288-90. PubMed ID: 9004577
    [No Abstract]   [Full Text] [Related]  

  • 12. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.
    Coukell AJ; Spencer CM
    Drugs; 1997 Mar; 53(3):520-38. PubMed ID: 9074848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DOXIL superior for KS.
    Posit Aware; 1995; ():7. PubMed ID: 11362576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma.
    Bogner JR; Kronawitter U; Rolinski B; Truebenbach K; Goebel FD
    J Acquir Immune Defic Syndr (1988); 1994 May; 7(5):463-8. PubMed ID: 8158540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic toxicity of liposomal encapsulated doxorubicin.
    Coker RJ; James ND; Stewart JS
    Lancet; 1993 Mar; 341(8847):756. PubMed ID: 8095649
    [No Abstract]   [Full Text] [Related]  

  • 16. Fatal hepatic failure with liposomal doxorubicin.
    Hengge UR; Brockmeyer NH; Rasshofer R; Goos M
    Lancet; 1993 Feb; 341(8841):383-4. PubMed ID: 8094161
    [No Abstract]   [Full Text] [Related]  

  • 17. DOXIL approved for KS.
    James JS
    AIDS Treat News; 1995 Dec; (no 236):6. PubMed ID: 11363051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxil receives FDA market clearance.
    AIDS Patient Care STDS; 1996 Apr; 10(2):135. PubMed ID: 11361702
    [No Abstract]   [Full Text] [Related]  

  • 19. Liposomal KS drugs approved.
    GMHC Treat Issues; 1996 Apr; 10(4):8-9. PubMed ID: 11363710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.
    Gill PS; Wernz J; Scadden DT; Cohen P; Mukwaya GM; von Roenn JH; Jacobs M; Kempin S; Silverberg I; Gonzales G; Rarick MU; Myers AM; Shepherd F; Sawka C; Pike MC; Ross ME
    J Clin Oncol; 1996 Aug; 14(8):2353-64. PubMed ID: 8708728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.